NCT01442987View on ClinicalTrials.gov

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
HypertensionHyperlipidemia
Interventions
DRUG

Irbesartan/Atorvastatin A

once daily, P.O. 8week

DRUG

Irbesartan

once daily, P.O. 8week

DRUG

Atorvastatin A

once daily, P.O. 8week

DRUG

Placebo

once daily, P.O. 8week

DRUG

Irbesartan/Atorvastatin B

once daily, P.O. 8week

DRUG

Atorvastatin B

once daily, P.O. 8week

Trial Locations (1)

Unknown

16 institutions including Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01442987 - Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia | Biotech Hunter | Biotech Hunter